NBYB Stock Overview
Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Northwest Biotherapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.45 |
| 52 Week High | US$1.02 |
| 52 Week Low | US$0.37 |
| Beta | -0.70 |
| 1 Month Change | -5.91% |
| 3 Month Change | -15.05% |
| 1 Year Change | -6.30% |
| 3 Year Change | -61.55% |
| 5 Year Change | 79.33% |
| Change since IPO | 39.81% |
Recent News & Updates
Recent updates
Shareholder Returns
| NBYB | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -2.2% | -0.2% | 0.5% |
| 1Y | -6.3% | -22.8% | 1.3% |
Price Volatility
| NBYB volatility | |
|---|---|
| NBYB Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Volatility Over Time: Insufficient data to determine NBYB's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 25 | Linda Powers | www.nwbio.com |
Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer.
Northwest Biotherapeutics, Inc. Fundamentals Summary
| NBYB fundamental statistics | |
|---|---|
| Market cap | €516.75m |
| Earnings (TTM) | -€60.05m |
| Revenue (TTM) | €1.80m |
297.3x
P/S Ratio-8.9x
P/E RatioIs NBYB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NBYB income statement (TTM) | |
|---|---|
| Revenue | US$1.93m |
| Cost of Revenue | US$27.73m |
| Gross Profit | -US$25.80m |
| Other Expenses | US$38.58m |
| Earnings | -US$64.37m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.053 |
| Gross Margin | -1,335.30% |
| Net Profit Margin | -3,331.94% |
| Debt/Equity Ratio | -86.7% |
How did NBYB perform over the long term?
See historical performance and comparison